Clinical Trials Browser

Phase 2 × Carcinoma, Neuroendocrine × Ipilimumab × Clear all

NCT04079712 2026-03-18

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Phase 2 Active not recruiting

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03591731 2025-04-01

NIPINEC

Phase 2 Completed

Carcinoma, Neuroendocrine